Clinical outcomes of novel subtypes in ALL202-U and ALL202-O studies. (A) Kaplan-Meier survival curves for OS; (A-C) and DFS; (D-F) for cases with and without CDX2-mut subtype (A,D), cases with and without IDH1/2-mut subtype (B,E), and cases with or without indicated subtypes (C,F). The prognostic impact on OS or DFS was evaluated using the log-rank test. Patients undergoing stem-cell transplantation (SCT) were not censored at the time of transplantation and were evaluated with inclusion of the posttransplantation period. CDX2, CDX2-high subtype; IDH1/2, IDH1/2-mut subtype.